Latest Articles and Analysis

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.

31,000 Veterans with HIV face unique barriers including comorbidities and HCV rates 3x the general population.

Study explores social-spatial networks and HIV/HCV diagnosis rates among homeless and injection drug users.

WHO 2030 HCV elimination goal at risk; only 5 of 110 countries on track as COVID-19 disrupts progress.

CANN roundtable discusses pandemic's impacts on HIV, HCV, STI, and SUD programs and funding weaknesses.

Stagnant CMS reimbursement rates since 2016 threaten addiction treatment provider closures and service access.

Restrictive Medicaid policies limit HCV treatment access through fibrosis restrictions and sobriety requirements.

UNAIDS report highlights HIV-HCV coinfection rates among people who inject drugs globally and in the US.

Reviews Biden's first 100 days on healthcare: infrastructure, subsidies, harm reduction, and health equity.

Analysis of Kanawha County HIV outbreak highlighting substance use, rural healthcare gaps, and pandemic impact.

Housing instability increases HIV/HCV acquisition by 55-65%; housing investments outpace health interventions.

Assesses pandemic's ongoing impact on HIV, HCV, and SUD surveillance and care with vaccine rollout.

NASTAD's hepatitis C navigation toolkit uses peer navigators and wraparound services for people who use drugs.

COVID-19 caused a 50% drop in hospital HCV screening and 72% drop in primary care settings.

Narrowly divided Senate limits Biden's health policy agenda, making regulatory actions the primary reform path.

Evaluates pandemic's impacts on HIV, HCV, and SUD services including testing disruptions and telehealth expansion.